Clinical Trial Update: Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pixantrone in combination with rituximab for indolent non-Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Pixantrone (pixantrone)
• Rituximab (rituximab)

Snippet

Sponsor: CTI BioPharma | Conditions: Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular | Phase 3 | Status: TERMINATED